A novel drug proven to reduce the risk of disease progression by 79% offers new hope to patients with inoperable metastatic advanced midgut neuroendocrine cancer.

Source: New lifeline for patients with inoperable neuroendocrine cancers


David Cottle

UBB Owner & Administrator